SOUTH SAN FRANCISCO, Calif., Nov. 7, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) is a clinical-stage biopharmaceutical company focused on developing novel therapies to Addressing Unmet Medical Needs and Viral Diseases in the Liver, today announced that the company will present six posters at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Conference®, to be held November 10-14, 2023 at Held in Boston, Massachusetts.
The posters include clinical and preclinical data for the non-alcoholic steatohepatitis (NASH) program ALG-055009, currently in a Phase 2 study, as well as preclinical and clinical data for the chronic hepatitis B (CHB) portfolio.Available on the Aligos website Scientific presentations and conferences Part after the meeting.
Poster details (All times are Eastern Time)
title: Safety, pharmacokinetics, and pharmacodynamics of multiple oral ascending doses of ALG-055009, a thyroid hormone receptor beta agonist, in subjects with hyperlipidemia and relative safety of solid dosage forms in healthy volunteers Bioavailability/food effects
Poster number: 2900-A
Abstract number: 41459
host: Stanley Wang, MD, PhD
Date and time: Saturday, November 11, 1-2 p.m.
title: ALG-055009 is a novel potent thyroid hormone receptor beta agonist for the treatment of non-alcoholic steatohepatitis (NASH) Non-clinical efficacy, pharmacokinetics/pharmacodynamics (PK/PD) and toxicology Overview
Poster number: 2461-C
Abstract number: 44177
host: Dr. Dinah Misner
Date and time: Saturday, November 11, 1-2 p.m.
title: First-in-class preclinical drug resistance and antiviral activity of CAM-E ALG-001075, the parent compound of ALG-000184
Poster number: 1482-C
Abstract number: 45229
host: Dr. Andreas Jeckel
Date and time: Friday, November 10, 1-2 p.m.
title: Class A CAM induces cell death through HBV core protein aggregation and may activate innate immune responses
Poster number: 1462-C
Abstract number: 44476
host: Dr. Taverniti Valerio
Date and time: Friday, November 10, 1-2 p.m.
title: Long-term (>24 weeks) oral administration of the CAM-E compound ALG-000184 reduces hepatitis B surface antigen, HBV DNA, and HBV RNA levels by several logs in untreated E-antigen-positive chronic hepatitis B subjects
Poster number: 1483-C
Abstract number: 41220
host: Niu Junqi, MD
Date and time: Friday, November 10, 12-1pm
title: Liver-targeted oral PD-L1 small molecule inhibitor discovered for treatment of chronic hepatitis B and liver cancer
Poster number: 1466-C
Abstract number: 44918
host: Wu Tongfei, Ph.D.
Date and time: FridayNovember 101-2 p.m.
About Arrigos
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with a mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to leverage its team’s deep expertise and decades of drug development experience in liver and viral diseases to discover and develop drugs targeting non-alcoholic steatohepatitis (NASH) and viruses with high unmet medical need, such as potential best treatments for coronaviruses and chronic viruses). Hepatitis B (CHB).
forward-looking statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be deemed “forward-looking statements.” Forward-looking statements are often, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate” and other similar words. “Expectations” and other similar terms referring to future results. Such forward-looking statements are subject to significant risks and uncertainties that could cause our development plans, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, those inherent in the drug development process, including Aligos’ clinical development stages, the process of designing and conducting clinical trials, the regulatory approval process, the timing of regulatory filings, challenges and drug products manufacturing-related matters, Aligos’ ability to successfully establish, protect and defend its intellectual property rights, other matters that may affect the adequacy of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development work and the changing landscape of the competitive landscape. Related For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as the overall risks associated with Aligos’ business, please see Aligos’ Quarterly Report on Form 10-Q filed on November 2, 2023. Reports filed with the Securities and Exchange Commission and future periodic reports to be filed with the Securities and Exchange Commission. Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events, except as required by law.
Media Contact
Veronica Eames
Life Sciences Newsletter
Veames@lifescicomms.com
Investor Contact
Dr. Corey Davis
life sciences consultant
+1 212 915 2577
cdavis@lifesciadvisors.com
